- Home
- CJET vs QNTM Comparison
CJET vs QNTM Comparison
Compare CJET & QNTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CJET
- QNTM
- Stock Information
- Founded
- CJET 2009
- QNTM 1998
- Country
- CJET China
- QNTM Canada
- Employees
- CJET N/A
- QNTM N/A
- Industry
- CJET Auto Manufacturing
- QNTM
- Sector
- CJET Consumer Discretionary
- QNTM
- Exchange
- CJET Nasdaq
- QNTM NYSE
- Market Cap
- CJET 11.0M
- QNTM 9.1M
- IPO Year
- CJET N/A
- QNTM N/A
- Fundamental
- Price
- CJET $2.01
- QNTM $3.48
- Analyst Decision
- CJET
- QNTM
- Analyst Count
- CJET 0
- QNTM 0
- Target Price
- CJET N/A
- QNTM N/A
- AVG Volume (30 Days)
- CJET 9.5K
- QNTM 97.9K
- Earning Date
- CJET 12-31-2024
- QNTM 12-31-2024
- Dividend Yield
- CJET N/A
- QNTM N/A
- EPS Growth
- CJET N/A
- QNTM N/A
- EPS
- CJET N/A
- QNTM N/A
- Revenue
- CJET $10,275,000.00
- QNTM N/A
- Revenue This Year
- CJET N/A
- QNTM N/A
- Revenue Next Year
- CJET N/A
- QNTM N/A
- P/E Ratio
- CJET N/A
- QNTM N/A
- Revenue Growth
- CJET 31.31
- QNTM N/A
- 52 Week Low
- CJET $1.77
- QNTM $3.42
- 52 Week High
- CJET $30.00
- QNTM $70.85
- Technical
- Relative Strength Index (RSI)
- CJET 47.19
- QNTM 30.23
- Support Level
- CJET $2.02
- QNTM $4.03
- Resistance Level
- CJET $2.07
- QNTM $4.50
- Average True Range (ATR)
- CJET 0.13
- QNTM 0.55
- MACD
- CJET -0.01
- QNTM -0.06
- Stochastic Oscillator
- CJET 25.88
- QNTM 2.63
About CJET Chijet Motor Company Inc.
Chijet Motor Co Inc is engaged in the research and development, production and sales of new energy vehicles. New energy vehicles refer to plug-in electric vehicles including battery electric vehicles, plug-in hybrid (PHEV) electric vehicles, and fuel cell electric vehicles. Its passenger vehicles include small cars, sedans, and sports utility vehicles, or SUVs, and commercial vehicles include light trucks and vans.
About QNTM QUANTUM BIOPHARMA LTD
Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.